United States Biotechnology & Medical Research

Viridian Therapeutics Inc (VRDN)

Track

Over the past 90 days, Viridian Therapeutics Inc. recorded one significant insider transaction involving a purchase of approximately $20 million in shares by Fairmount Funds Management LLC. This activity follows the company's recent earnings report, which showed an EPS beat of 17.43%. No executive-level insider selling or buying was reported during this period.
Ticker: VRDN Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Viridian Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 11 May 2026
Value US$3,859,216.16 | Price 259.02 | Shares 86,034 (+11.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-13 2026-05-11 B Purchase
3.4
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
86,034 +11.6%
259.02
US$3,859,216 		86,034 +11.6% 259.02 US$3,859,216
2026-03-04 2026-03-04 PrS Proposed sale
Beetham Thomas W.

Officer

Officer
46,652
217.60
US$2,905,722 		46,652 217.60 US$2,905,722
2026-03-04 2026-03-04 PrS Proposed sale
Tousignant Jennifer

Officer

Officer
26,640
366.45
US$1,828,818 		26,640 366.45 US$1,828,818
2026-03-04 2026-03-04 PrS Proposed sale
Harmon Seth

Officer

Officer
2,031
30.19
US$61,306 		2,031 30.19 US$61,306
2026-03-04 2026-03-04 PrS Proposed sale
0.9
Mahoney Stephen F.

Officer; Director

Executive Director
7,408
30.19
US$223,610 		7,408 30.19 US$223,610
2026-01-02 2025-12-31 PlS Planned sale
Tousignant Jennifer

Chief Legal Officer

Officer
2,272 -100.0%
31.16
US$70,796 		2,272 -100.0% 31.16 US$70,796
2025-10-27 2025-10-23 B Purchase
3.4
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
454,545 +13.1%
22.00
US$9,999,990 		454,545 +13.1% 22.00 US$9,999,990
2024-09-30 2024-09-27 PP Planned purchase
Beetham Thomas W.

Chief Operating Officer

Officer
5,000 +500.0%
23.41
US$117,050 		5,000 +500.0% 23.41 US$117,050
2024-09-30 2024-09-27 B Purchase
0.9
Mahoney Stephen F.

President and CEO

Executive Director
21,400 +inf%
23.33
US$499,262 		21,400 +inf% 23.33 US$499,262
2024-09-17 2024-09-13 B Purchase
3.4
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
1,600,000 +86.7%
18.75
US$30,000,000 		1,600,000 +86.7% 18.75 US$30,000,000
2024-01-24 2024-01-22 B Purchase
3.4
Fairmount Funds Management LLC

See Remarks

Non-Executive Director Large shareholder
476,190 +34.9%
21.00
US$9,999,990 		476,190 +34.9% 21.00 US$9,999,990
2023-12-18 2023-12-18 PrS Proposed sale
3.5
Meisner Lara

Former Officer

Officer
9,375
21.16
US$198,375 		9,375 21.16 US$198,375
2023-12-12 2023-12-12 PrS Proposed sale
Humer Kristian

Former CFO
252,600
17.16
US$4,334,667 		252,600 17.16 US$4,334,667
2023-12-07 2023-12-07 PrS Proposed sale
Humer Kristian

Former Officer

Officer
24,900
18.91
US$470,858 		24,900 18.91 US$470,858
2023-12-01 2023-12-01 PrS Proposed sale
3.5
Meisner Lara

Former Officer

Officer
3,125
16.97
US$53,031 		3,125 16.97 US$53,031
2023-11-16 2023-11-16 PrS Proposed sale
1.7
Myers Scott Dunseth

Former Officer and Director

Executive Director
35,368
15.13
US$535,118 		35,368 15.13 US$535,118
2023-06-20 2023-06-16 S Sale
3.5
Meisner Lara

Chief Legal Officer

Officer
27 -0.1%
28.35
US$765 		27 -0.1% 28.35 US$765
2023-06-20 2023-06-15 PlS Planned sale
3.5
Meisner Lara

Chief Legal Officer

Officer
2,269 -7.0%
28.02
US$63,577 		2,269 -7.0% 28.02 US$63,577
2023-06-06 2023-06-06 S Sale
3.5
Meisner Lara

Chief Legal Officer

Officer
5,126 -14.6%
25.02
US$128,253 		5,126 -14.6% 25.02 US$128,253
2023-06-06 2023-06-05 S Sale
3.5
Meisner Lara

Chief Legal Officer

Officer
499 -1.6%
25.03
US$12,490 		499 -1.6% 25.03 US$12,490
2023-06-06 2023-06-02 PlS Planned sale
3.5
Meisner Lara

Chief Legal Officer

Officer
1,875 -5.9%
24.21
US$45,394 		1,875 -5.9% 24.21 US$45,394
2023-06-02 2023-06-02 PrS Proposed sale
3.5
Meisner Lara

Officer

Officer
12,469
24.50
US$305,490 		12,469 24.50 US$305,490
2023-04-12 2023-04-12 B Purchase
1.7
Myers Scott Dunseth

Chief Executive Officer

Executive Director
4,000 +1.6%
25.37
US$101,479 		4,000 +1.6% 25.37 US$101,479
2023-03-13 2023-03-13 B Purchase
1.7
Myers Scott Dunseth

Chief Executive Officer

Executive Director
5,500 +2.2%
29.15
US$160,324 		5,500 +2.2% 29.15 US$160,324
2023-03-10 2023-03-09 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
29,971 -100.0%
29.07
US$871,257 		29,971 -100.0% 29.07 US$871,257
2023-02-03 2023-02-02 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
50,000 -10.4%
36.80
US$1,840,000 		50,000 -10.4% 36.80 US$1,840,000
2023-01-25 2023-01-23 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
6,843 -100.0%
35.66
US$244,021 		6,843 -100.0% 35.66 US$244,021
2023-01-18 2023-01-17 PlS Planned sale
Katz Barrett

Chief Medical Officer

Officer
24,853 -100.0%
37.21
US$924,780 		24,853 -100.0% 37.21 US$924,780
2023-01-18 2023-01-13 PlS Planned sale
Katz Barrett

Chief Medical Officer

Officer
4,147 -100.0%
37.01
US$153,480 		4,147 -100.0% 37.01 US$153,480
2023-01-11 2023-01-10 PlS Planned sale
Katz Barrett

Chief Medical Officer

Officer
47,377 -100.0%
35.30
US$1,672,408 		47,377 -100.0% 35.30 US$1,672,408
2023-01-11 2023-01-09 PlS Planned sale
Katz Barrett

Chief Medical Officer

Officer
12,623 -100.0%
33.04
US$417,064 		12,623 -100.0% 33.04 US$417,064
2022-12-22 2022-12-21 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
16,326 -100.0%
29.19
US$476,556 		16,326 -100.0% 29.19 US$476,556
2022-12-22 2022-12-20 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
600 -100.0%
28.07
US$16,842 		600 -100.0% 28.07 US$16,842
2022-12-19 2022-12-16 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
1,297 -100.0%
28.44
US$36,887 		1,297 -100.0% 28.44 US$36,887
2022-12-19 2022-12-15 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
300 -100.0%
28.08
US$8,424 		300 -100.0% 28.08 US$8,424
2022-12-14 2022-12-14 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
15,656 -100.0%
28.12
US$440,247 		15,656 -100.0% 28.12 US$440,247
2022-12-14 2022-12-12 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
600 -100.0%
28.05
US$16,830 		600 -100.0% 28.05 US$16,830
2022-11-16 2022-11-15 PlS Planned sale
3.5
Meisner Lara

General Counsel and Secretary

Officer
8,125 -100.0%
22.05
US$179,156 		8,125 -100.0% 22.05 US$179,156
2022-08-19 2022-08-17 B Purchase
3.4
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
425,531 +45.4%
23.50
US$9,999,978 		425,531 +45.4% 23.50 US$9,999,978
2022-06-02 2022-06-01 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
30,000 -5.9%
12.20
US$366,000 		30,000 -5.9% 12.20 US$366,000
2022-05-04 2022-05-02 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
30,000 -5.5%
13.04
US$391,200 		30,000 -5.5% 13.04 US$391,200
2022-04-05 2022-04-04 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
3,600 -0.7%
18.93
US$68,148 		3,600 -0.7% 18.93 US$68,148
2022-04-05 2022-04-01 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
26,400 -4.6%
18.92
US$499,488 		26,400 -4.6% 18.92 US$499,488
2022-03-03 2022-03-02 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
11,106 -1.9%
17.36
US$192,800 		11,106 -1.9% 17.36 US$192,800
2022-03-03 2022-03-01 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
18,894 -3.1%
17.82
US$336,691 		18,894 -3.1% 17.82 US$336,691
2022-02-03 2022-02-03 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
909 -0.2%
19.16
US$17,416 		909 -0.2% 19.16 US$17,416
2022-02-03 2022-02-02 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
12,340 -2.0%
18.47
US$227,920 		12,340 -2.0% 18.47 US$227,920
2022-02-03 2022-02-01 PlS Planned sale
Violin Jonathan

Chief Executive Officer

Executive Director
16,751 -2.7%
19.55
US$327,482 		16,751 -2.7% 19.55 US$327,482
2021-09-28 2021-09-23 B Purchase
Frazier Life Sciences Public Fund, L.P.
Large shareholder
200,000 +15.3%
11.00
US$2,200,000 		200,000 +15.3% 11.00 US$2,200,000
2020-11-16 2020-11-13 B Purchase
3.5
Logos Global Master Fund LP
Large shareholder
126,667 +29.9%
14.84
US$1,879,599 		126,667 +29.9% 14.84 US$1,879,599
2020-11-16 2020-11-09 B Purchase
3.5
Logos Global Master Fund LP
Large shareholder
100,000 +1.6%
1.16
US$116,410 		100,000 +1.6% 1.16 US$116,410
2020-11-16 2020-11-09 B Purchase
3.5
Logos Global Master Fund LP
Large shareholder
250,000 +4.2%
1.10
US$274,475 		250,000 +4.2% 1.10 US$274,475
2018-10-12 2018-10-11 B Purchase Hughes Thomas E. Non-Executive Director
10,000 +353.7%
4.77
US$47,697 		10,000 +353.7% 4.77 US$47,697
2018-02-13 2018-02-13 B Purchase Levy Adam Scott

Chief Business Officer

Officer
9,090 +626.9%
5.50
US$49,995 		9,090 +626.9% 5.50 US$49,995
2018-02-13 2018-02-13 B Purchase Booth Bruce Non-Executive Director
545,454 +67.7%
5.50
US$2,999,997 		545,454 +67.7% 5.50 US$2,999,997
2017-12-22 2017-12-20 S Sale Hughes Thomas E.
12,000 -80.9%
8.00
US$96,000 		12,000 -80.9% 8.00 US$96,000
2017-06-23 2017-06-22 B Purchase Levy Adam Scott

Chief Business Officer
200 +inf%
7.55
US$1,510 		200 +inf% 7.55 US$1,510
2017-03-13 2017-03-10 S Sale LEFKOFF KYLE Non-Executive Director
3,300 -0.7%
14.31
US$47,229 		3,300 -0.7% 14.31 US$47,229
2017-03-13 2017-03-09 S Sale LEFKOFF KYLE Non-Executive Director
2,500 -0.5%
14.38
US$35,962 		2,500 -0.5% 14.38 US$35,962
2017-03-08 2017-03-08 S Sale LEFKOFF KYLE Non-Executive Director
5,000 -1.1%
14.70
US$73,514 		5,000 -1.1% 14.70 US$73,514
2017-03-08 2017-03-06 S Sale LEFKOFF KYLE Non-Executive Director
608 -0.1%
16.24
US$9,874 		608 -0.1% 16.24 US$9,874
2017-03-08 2017-03-06 S Sale LEFKOFF KYLE Non-Executive Director
9,392 -1.9%
15.71
US$147,590 		9,392 -1.9% 15.71 US$147,590
2017-02-28 2017-02-28 S Sale LEFKOFF KYLE Non-Executive Director
2,258 -0.5%
13.54
US$30,580 		2,258 -0.5% 13.54 US$30,580
2017-02-28 2017-02-27 S Sale LEFKOFF KYLE Non-Executive Director
1,500 -0.3%
13.79
US$20,686 		1,500 -0.3% 13.79 US$20,686
2017-02-28 2017-02-24 S Sale LEFKOFF KYLE Non-Executive Director
6,500 -1.3%
14.04
US$91,252 		6,500 -1.3% 14.04 US$91,252
2017-02-24 2017-02-23 S Sale LEFKOFF KYLE Non-Executive Director
1,800 -0.4%
13.65
US$24,566 		1,800 -0.4% 13.65 US$24,566
2017-02-24 2017-02-22 S Sale LEFKOFF KYLE Non-Executive Director
4,102 -0.8%
14.36
US$58,886 		4,102 -0.8% 14.36 US$58,886
2015-11-23 2015-11-20 B Purchase Riccitelli Samuel D

President & CEO

Executive Director
7,000 +2.1%
0.80
US$5,600 		7,000 +2.1% 0.80 US$5,600
2015-11-23 2015-11-19 B Purchase Riccitelli Samuel D

President & CEO

Executive Director
7,000 +2.1%
0.78
US$5,460 		7,000 +2.1% 0.78 US$5,460
Explore more

More insider trading research around Viridian Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America